Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of inhaled AZ-009 in Parkinson's disease
NL-OMON48411Completed
- Sponsor
- Alexza Pharmaceuticals Inc
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Parkinson's disease (PD) comparing AZ-009 with Placebo (2 arms). Primary endpoints: Safety and tolerability after several days of dosing, Pharmacokinetics in Part A and 4 more. Started Sep 2019; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON48411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48411.